Brief: Newron Notes the Publication of New Preclinical Research
11/08/2025 12:18
Aug 11 (Reuters) - Newron Pharmaceuticals SpA NWRN.S: NEWRON NOTES THE PUBLICATION OF NEW PRECLINICAL RESEARCH SUGGESTING EVENAMIDE AMELIORATES SCHIZOPHRENIA-RELATED DYSFUNCTION Source text: ID:nBw2N5RPJa Further company coverage: NWRN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study